TOTAL: $42.07M
Year to Date: $126.23M
Company
(Symbol)#*		 Partner
(Country)		 Amt.
(M)		 Triggering
Event		 Details (Date)
Athersys Inc.* Bristol-Myers Squibb Co.; and Angiotech Pharmaceuticals Inc. (Canada; ANPI) ND Milestone payments Athersys received payments for BMS' sub- mission of an IND for a compound discovered using Athersys' RAGE target, and after completing multiple animal studies showing that MultiStem can be delivered safely to the heart via catheter (3/29)
BioSante
Pharmaceuticals
Inc. (AMEX:BPA)		 Bradley Pharmaceuticals Inc. $7 Milestone payment BioSante received the payment under the terms of its Elestrin (estradiol gel) licensing agreement (3/26)
Cellzome Inc.* Ortho-McNeil Pharmaceutical Inc. ND Milestone payment Cellzome received the first milestone in a deal from May 2005 focused on gamma secretase modulators; it was triggered by Ortho- McNeil's selection of a lead compound (3/13)
Crucell NV
(the Netherlands;
CRXL)		 Aeras Global TB Vaccine Foundation* $5 Investment Aeras invested another $5M in the collaboration it formed with Crucell in 2004 to develop a PER.C6 and AdVac-based vaccine (3/7)
EvoGenix Ltd.*
(Australia)		 GlaxoSmithKline plc (UK) ND Milestone payment EvoGenix received the payment upon GSK's confirmation of successful completion of the companies' first project, development of an improved version of a GSK product (3/26)
Galapagos NV
(Belgium; LSE: GLPG)		 GlaxoSmithKline plc (UK) $4.27 Milestone payments Galapagos received the payments in relation to its multi-year drug discovery alliance with GSK in osteoarthritis (3/30)
Gilead Sciences
Inc. (GILD)		 GlaxoSmithKline plc (UK) ND Milestone payment Triggered by the European Medicines Agency's validation of the marketing authorization application for ambrisentan to treat pulmonary arterial hypertension (3/23)
IGI Inc.
(AMEX:IG)		 Pharmachem Laboratories Inc.* $1.5 Equity investment Pharmachem purchased 1.5M shares of IGI's common stock to be used to repay outstanding debts and accrued interest, as part of IGI's efforts to comply with AMEX requirements for continued listing (3/9)
Medivir AB
(Sweden;
SSE:MVIRB) 		Epiphany Biosciences Inc.* $0.5 Milestone payment Triggered by progress in their license agreement on the shingles project MIV-606 (EPB- 348); Medivir also gained a 2% ownership stake in Epiphany (3/19)
Neuromed
Pharmaceuticals*		 Merck & Co. Inc. $2 Milestone payment The milestone was triggered by progress in their March 2006 collaboration on N-type calcium channel blockers for treating pain and other disorders (3/14)
NicOx SA
(France; FSE:NXO)		 Pfizer Inc. €1($1.3) Milestone payment NicOx earned the payment for the start of a series of trials of PF-03187207, a drug candidate for glaucoma (3/28)
Pharmacopeia
Drug Discovery
Inc. (PCOP)		 Schering-Plough Corp. $1 Milestone payment Pharmacopeia received the payment for the start of a Phase I trial of PS386113, a compound to treat inflammatory disease (3/28)
Protherics plc
(UK; PTIL; LSE:PTI)		 AstraZeneca plc (UK) $19.3 Milestone payment The milestone was triggered by Protherics' scale-up of manufacturing for sepsis drug CytoFab to a 600 litre (158.5 gallon) batch size; the drug is slated to begin expanded Phase IIb studies in septic shock in the second half of the year (3/12)
Vical Inc. (VICL) Merck & Co. Inc. and Sanofi-Aventis (France) $0.2 Milestone payment Vical received the payment for the con- ditional approval from the U.S. Department of Agriculture to market a therapeutic DNA vaccine designed to treat melanoma in dogs (3/26)
Notes:
# Unless otherwise indicated, shares are traded on the Nasdaq exchange.
Currency conversions are based on exchange rates at the time of the deal. U.S. dollars are in brackets.
ND = Not disclosed.
AMEX = American Stock Exchange; LSE = London Stock Exchange; FSE = Frankfurt Stock Exchange; SSE = Stockholm Stock Exchange